
į.





Attorney Docket No.: 6258.200-US

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE FILING UNDER 37 C.F.R. 1.53(b)

**Box Patent Application** Commissioner for Patents Washington, DC 20231

Express Mail Label No. EL636737709US Date of Deposit. November 16, 2001

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of

Applicant(s): Peter Madsen et al.

Title: Glucagon Antagonists/Inverse Agonists

72 pages of specification \_-0- sheet of Formal Drawings

3 sheets of Declaration and Power of Attorney

1 sheet of Abstract

[x]The filing fee is calculated as follows:

Basic Fee: \$ 740.00

Total Claims:  $22-20 = 2 \times 18 =$ 36.00

Independent Claims:  $2 - 3 = 0 \times 84 =$ \$ -0-

\$ 776.00 Total Fee:

Priority of Danish application no. PA 2000 01731 filed on November 17, 2000 is claimed under 35 U.S.C. 119. Certified copy will be submitted at a later date.

Priority of U.S. provisional application no. 60/252,343 filed on November 20, 2000 is claimed under 35 U.S.C. 119.

 Address all future communications to Reza Green, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$776, and any other applicable fees, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 16, 2001

Richard W. Bork Reg. No. 36,459 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401 (212) 867-0123

23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 6258.200-US PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE EXPRESS MAIL CERTIFICATE

Box Patent Application Commissioner for Patents Washington, DC 20231

Re: U.S. Patent Application for

Title: Glucagon Antagonists/Inverse Agonists

Applicants: Peter Madsen et al.

Sir:

Express Mail Label No. **EL636737709US**Date of Deposit: **November 16, 2001** 

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)

- 2. Patent Application (72 pages of Spec/1 sheet abstract/)
- 3. Unexecuted Combined Declaration and Power of Attorney
- 4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Sylvija Gonzalez

(Name of person mailing paper(s) or fee)

(Sygnature of person mailing paper(s) or fee)

Mailing Address: Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123